Although it has been proposed that targeting self-renewal pathways in CSCs, such as the Wnt, Notch, and Hedgehog pathways [46], or specific CSC markers, such as CD133 (Prominin-1) [47], CXCR1 [48, 49], and CD44 [50], may offer therapeutic benefits to cancer therapy, evidence for the benefits of blocking these pathways and markers in HNSCC has not been reported so far. Here, CXCR1 is linked to head and neck squamous cell carcinoma.